More than 2 million Americans struggle with opioid use disorder (OUD), a chronic relapsing medical condition, but access to medication-assisted treatment—the most effective therapy—remains limited. Buprenorphine, one of three drugs approved by the Food and Drug Administration to treat OUD, helps alleviate painful symptoms associated with the disorder. But few clinicians prescribe the drug. Ironically, federal legislation intended to expand access to treatment for OUD—the Drug Addiction Treatment Act of 2000—has discouraged buprenorphine prescribing because it requires health care providers to get additional training and receive permission from the Drug Enforcement Administration (DEA), known as the X-waiver, before they can prescribe the drug in outpatient settings. And these requirements exacerbate other barriers.